Positive impactIPO
Symbiotec Pharmalab shares to list today; GMP signals 19% premium over IPO price
CNBC-TV18 2 hrs ago·1 Sept 2026, 1:32 am
Symbiotec Pharmalab is set to list on the stock exchanges today, marking the conclusion of its initial public offering (IPO). The company raised funds through this public issue to support its business expansion plans.
For investors, the grey market premium (GMP) of ₹185 suggests the stock may open with a notable gain. This premium implies a potential listing price around ₹1,173, which is approximately 19% higher than the IPO price of ₹988. Such a premium indicates strong demand and positive sentiment in the secondary market.
Investors should monitor the opening price and the volume of trading on the listing day. The stock's performance in the first few sessions will be crucial to gauge the market's initial reaction to the listing.
Excerpt from CNBC-TV18
If grey market trends are anything to go by, the stock could make a strong debut with a premium of around 19% over its issue price. The grey market premium (GMP) currently stands at ₹185, indicating an estimated listing price of around ₹1,173 per share, compared with the IPO price of ₹988. Disclaimer: The views and…Read the original at CNBC-TV18
Key takeaways
- Category: IPO.
- AI reads the tone as positive (potentially bullish) for the stock.
Why it matters
A routine update. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.
